Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis
Yin-Chen Wang(Taipei Veterans General Hospital), Yi‐Hsiang Huang(First Hospital of Lanzhou University)
Cited by 49
Related Papers
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|221
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|Journal of the Formosan Medical Association|2020|98
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
|Journal of Hepatology|2023|62